Zydus Lifesciences Ltd. has launched Zyrifa, a biosimilar of the monoclonal antibody Denosumab 120 mg SC. This new subcutaneous injection offers a more affordable treatment option designed to manage and prevent severe bone-related complications (skeletal-related events) in patients whose cancer has metastasized to the bones.

Bone metastases are a common and serious issue in advanced cancers—affecting up to 70% of advanced breast or prostate cancer patients—leading to significant pain, fractures, reduced mobility, and a diminished quality of life.

Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors, including breast, prostate, lung, kidney, thyroid, and head & neck cancers.

Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences, stated, "Our goal with Denosumab 120 mg SC is to increase access and affordability for cancer patients requiring critical care. This medication will support patients in maintaining mobility and dignity as they battle their disease."

The new biosimilar is priced at an MRP of ₹12,495. This launch expands Zydus’s existing portfolio of biosimilar cancer treatments.